Sport Investors League
  • Politics
  • Stocks
  • Investing
  • Business

Sport Investors League

  • Politics
  • Stocks
  • Investing
  • Business
Investing

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

by admin September 16, 2025
September 16, 2025
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) (‘Lobe Sciences’ or the ‘Company’) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company’s recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

Alongside the schedule of pre-booked meetings matching investors with appropriate projects, the conference program will provide amble opportunities to mix and mingle with the industry professionals and catch up on key industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register to request for a free invitation here.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in Toronto and New York. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About lobe sciences ltd.

Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:

  • Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.

Lobe’s pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.

For additional Information, please contact:

lobe sciences ltd.
info@lobesciences.com
www.lobesciences.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265683

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Angkor Resources: Unlocking Cambodia’s Resource Potential through Energy and Minerals Assets
next post
John Feneck: Next Gold, Silver Price Targets, 11 Stocks I’m Bullish on Now

Related Posts

Lac Carheil Graphite Project Awarded Grant Funding

March 6, 2025

Crypto Market Update: FalconX to Buy 21Shares, Senate...

October 23, 2025

Locksley Resources

September 6, 2025

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies

May 28, 2025

Prismo Metals Announces Closing of Upsized Private Placement...

July 19, 2025

Altech – CERENERGY Accredited Highest Possible Green Rating

January 24, 2025

Fund Manager: Gold Stocks a Strategic Opportunity for...

May 21, 2025

Top 5 Canadian Mining Stocks This Week: Sanu...

December 7, 2024

Opawica Explorations: Advancing High-potential Gold Assets in the...

December 19, 2024

Scoping Study Demonstrates Low Cost ISR Uranium Potential

June 5, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent

    • Expert warns Democrats risk backlash over failure to condemn violent rhetoric in their ranks

      October 26, 2025
    • Here’s when 2025 Election Day early in-person voting comes to a close across the US

      October 26, 2025
    • Serbian foreign minister proposes hosting Ukraine-Russia peace negotiations amid ongoing conflict

      October 26, 2025
    • Trump tears down East Wing for $300M ballroom ahead of high-stakes China meeting

      October 26, 2025
    • Cuomo rips Mamdani’s victim narrative, says Dem socialist is ‘offender’ against 9/11 families, Jews and more

      October 26, 2025

    Categories

    • Business (1,125)
    • Investing (3,336)
    • Politics (4,072)
    • Stocks (1,155)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sportinvestorsleague.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 sportinvestorsleague.com | All Rights Reserved